Veraxa Biotech Holding AG (FRA:J8L0) Stock Based Compensation: €56.28 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8L0 Veraxa Biotech Holding AG FRA:J8L0
13 GF Score
Price €1.62
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Stock Based Compensation?

Veraxa Biotech Holding AG FRA:J8L0 -2.06% 13 Stock Based Compensation is €56.28 Mil as of Dec. 2025. GuruFocus rates FRA:J8L0 with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Veraxa Biotech Holding AG's Stock Based Compensation for the six months ended in Dec. 2025 was €25.09 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €56.28 Mil.

Veraxa Biotech Holding AG Stock Based Compensation Related Terms

Veraxa Biotech Holding AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Stock Based Compensation Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Stock Based Compensation
8.07 19.63 56.44

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation 0.00 6.02 13.43 31.19 25.09
FRA:J8L0
13GF Score
Veraxa Biotech Holding AG FRA:J8L0
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €56.28 Mil.

What does a Stock Based Compensation of €56.28 Mil mean?
Veraxa Biotech Holding AG (FRA:J8L0) has a Stock Based Compensation of €56.28 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's Stock Based Compensation too high?
Veraxa Biotech Holding AG's current Stock Based Compensation is €56.28 Mil. Overall, Veraxa Biotech Holding AG has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Stock Based Compensation compare to TTRX and IRD?
Veraxa Biotech Holding AG's Stock Based Compensation of €56.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Stock Based Compensation is €56.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (FRA:J8L0) has a current Stock Based Compensation of €56.28 Mil. The current Stock Based Compensation is €56.28 Mil. Veraxa Biotech Holding AG's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Veraxa Biotech Holding AG (FRA:J8L0), the current Stock Based Compensation is €56.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges VRXA:USA
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
13GF Score

Get the complete analysis for FRA:J8L0

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price